CytoDyn (STU:296) Other Financing : €9.41 Mil (TTM As of Feb. 2025)

View and export this data going back to 2016. Start your Free Trial

What is CytoDyn Other Financing?

CytoDyn's Other Financing for the three months ended in Feb. 2025 was €0.00 Mil.

CytoDyn's Other Financing for the trailing twelve months (TTM) ended in Feb. 2025 was €9.41 Mil.

CytoDyn Other Financing Historical Data

The historical data trend for CytoDyn's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Other Financing Chart

CytoDyn Annual Data

Trend

May15

May16

May17

May18

May19

May20

May21

May22

May23

May24

Other Financing

Get a 7-Day Free Trial

37.40

30.90

6.45

2.99

0.56

CytoDyn Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Other Financing	Get a 7-Day Free Trial															0.28	-	9.41	-	-

CytoDyn Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.41 Mil.

CytoDyn Other Financing Related Terms

Thank you for viewing the detailed overview of CytoDyn's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

CYDY:USA

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CytoDyn Headlines

No Headlines